RCKT
Rocket Pharmaceuticals Inc

3,140
Mkt Cap
$379.86M
Volume
860,136.00
52W High
$13.35
52W Low
$2.19
PE Ratio
-1.56
RCKT Fundamentals
Price
$3.51
Prev Close
$3.45
Open
$3.50
50D MA
$3.42
Beta
1.16
Avg. Volume
2.1M
EPS (Annual)
-$2.73
P/B
1.21
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Rocket Pharmaceuticals (NASDAQ:RCKT) Raised to Hold at TD Cowen
TD Cowen upgraded shares of Rocket Pharmaceuticals to a "hold" rating in a research note on Friday...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Rating of "Hold" from Brokerages
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) have earned an average rating of "Hold" from the eighteen brokerages that are presently covering the company, Marketbeat.com...
MarketBeat·12d ago
News Placeholder
Maverick Capital Ltd. Has $20.49 Million Stock Position in Rocket Pharmaceuticals, Inc. $RCKT
Maverick Capital Ltd. boosted its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 60.9% during the second quarter, according to the company in its most recent Form...
MarketBeat·13d ago
News Placeholder
Rocket Pharmaceuticals (NASDAQ:RCKT) Share Price Passes Below Fifty Day Moving Average - Here's Why
Rocket Pharmaceuticals (NASDAQ:RCKT) Share Price Passes Below 50-Day Moving Average - Here's What Happened...
MarketBeat·17d ago
News Placeholder
Bank of America Issues Pessimistic Forecast for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price
Bank of America lowered their price objective on shares of Rocket Pharmaceuticals from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Tuesday...
MarketBeat·1mo ago
News Placeholder
JPMorgan Chase & Co. Downgrades Rocket Pharmaceuticals (NASDAQ:RCKT) to Underweight
JPMorgan Chase & Co. lowered Rocket Pharmaceuticals from a "neutral" rating to an "underweight" rating in a research report on Tuesday...
MarketBeat·1mo ago
News Placeholder
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Rating of "Hold" from Brokerages
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) have earned a consensus rating of "Hold" from the eighteen research firms that are covering the stock, MarketBeat reports. Three...
MarketBeat·1mo ago
News Placeholder
Quinn Opportunity Partners LLC Takes Position in Rocket Pharmaceuticals, Inc. $RCKT
Quinn Opportunity Partners LLC bought a new stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with...
MarketBeat·1mo ago
News Placeholder
Rocket Pharmaceuticals (NASDAQ:RCKT) Earns Outperform Rating from Wedbush
Wedbush reaffirmed an "outperform" rating and set a $16.00 price target on shares of Rocket Pharmaceuticals in a research report on Friday...
MarketBeat·2mo ago
News Placeholder
Rocket Pharmaceuticals (NASDAQ:RCKT) Announces Earnings Results, Beats Expectations By $0.03 EPS
Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, topping...
MarketBeat·2mo ago
<
1
2
...
>

Latest RCKT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.